- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Diagnosis and Management of Type I and Type V Hyperlipoproteinemia
-
- Gotoda Takanari
- Department of Clinical and Molecular Epidemiology, 22nd Century Medical and Research Center, University of Tokyo Hospital.
-
- Shirai Koji
- Internal Medicine, Sakura Hospital, School of Medicine, Toho University.
-
- Ohta Takao
- Department of Child Health and Welfare (Pediatrics), Faculty of Medicine, University of the Ryukyus.
-
- Kobayashi Junji
- Department of Lipidology, Kanazawa University Graduate School of Medical Science.
-
- Yokoyama Shinji
- Department of Biochemistry, Nagoya City University Graduate School of Medical Sciences. Food and Nutritional Sciences, College of Biosciences and Biotechnology, Chubu University.
-
- Oikawa Shinichi
- Division of Endocrinology and Metabolism, Department of Medicine, Nippon Medical School.
-
- Bujo Hideaki
- Department of Genome Research and Clinical Application, Chiba University Graduate School of Medicine.
-
- Ishibashi Shun
- Division of Endocrinology and Metabolism, Diabetes Center, Department of Medicine, Jichi Medical University Graduate School of Medicine.
-
- Arai Hidenori
- Department of Human Health Sciences, Kyoto University Graduate School of Medicine.
-
- Yamashita Shizuya
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
-
- Harada-Shiba Mariko
- Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.
-
- Eto Masaaki
- School of Pharmaceutical Sciences, Ohu University and Department of Medicine, Ohu University Hospital.
-
- Hayashi Toshio
- Department of Geriatrics, Nagoya University Graduate School of Medicine.
-
- Sone Hirohito
- Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine.
-
- Suzuki Hiroaki
- Department of Endocrinology and Metabolism, Graduate School of Comprehensive Human Sciences, University of Tsukuba.
-
- Yamada Nobuhiro
- University of Tsukuba.
Bibliographic Information
- Other Title
-
- Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan. Diagnosis and management of type I and type V hyperlipoproteinemia
Search this article
Description
Both type I and type V hyperlipoproteinemia are characterized by severe hypertriglyceridemia due to an increase in chylomicrons. Type I hyperlipoproteinemia is caused by a decisive abnormality of the lipoprotein lipase (LPL)- apolipoprotein C-II system, whereas the cause of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. Since the relationship of hypertriglyceridemia with atherosclerosis is not as clear as that of hypercholesterolemia, and since type I and V hyperlipoproteinemia are relatively rare, few guidelines for their diagnosis and treatment have been established; however, type I and V hyperlipoproteinemia are clinically important as underlying disorders of acute pancreatitis, and appropriate management is necessary to prevent or treat such complications. Against such a background, here we propose guidelines primarily concerning the diagnosis and management of type I and V hyperlipoproteinemia in Japanese.
Journal
-
- Journal of Atherosclerosis and Thrombosis
-
Journal of Atherosclerosis and Thrombosis 19 (1), 1-12, 2012
Japan Atherosclerosis Society
